Category: News Well
Content tagged to appear in the middle column of the home page
Researchers for the massive DAPT study find that drug-eluting stents may be safer than bare-metal stents, calling into question the value of Boston Scientific's next-gen Synergy stent.
Researchers for the massive Dual Anti-platelet Therapy Study found that patients receiving drug-eluting stents had a lower rate of stent thrombosis and other major cardiovascular events than those treated with bare-metal stents, undermining the common perception that bare-metal stents are safer.
HCA Holdings halts the use of laparoscopic power morcellators in uterine fibroid surgeries in all 278 of its facilities, after the FDA raises the warning level on the cancer risk associated with the devices.
(Reuters) — HCA Holdings (NYSE:HCA), the largest for-profit U.S. hospital operator, said a procedure for removing uterine fibroids that's been linked to the spread of cancer will no longer be performed at its facilities.
Vascular Solutions says the FDA granted 510(k) clearance for its Gel-Block embolization foam.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Medtronic says it expects to repatriate as much as $4 billion in cash after it resolves a dispute with the IRS involving its Puerto Rico subsidiary.
Medtronic (NYSE:MDT) said today that it expects to land a substantial windfall once it resolves a dispute with the IRS over the next "couple of years."
The plaintiffs in 185 lawsuits filed against C.R. Bard over its Avaulta pelvic mesh as part of a multi-district litigation want their cases tried together.